pharma news today obesity drugs glp-1 october 2025 GLP‑1 real‑world data for obesity: A new standard for metabolic care GLP-1 therapies are changing obesity

Failure of these systems results in the accumulation of misfolded or aggregated proteins, organelle dysfunction, cellular injury, and disease progression across a wide spectrum of conditions, including neurodegeneration, cancer, cardiovascular and metabolic diseases

Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells

For example, we may recommend combining targeted peptide injections with platelet-rich fibrin (PRF) or platelet-derived growth factors (PDGF)

Glutathione helps reduce hyperpigmentation and promotes a lighter, more even complexion

A 70 kg adult in Schneider-Helmerts protocol received approximately 1,485 mcg intravenously

Its production decreases with age, and in some cases, it is insufficient to adequately defend the body